Aktienanalyse zu BlossomHill Therapeutics Inc (BLSM)BLSMBlossomHill Therapeutics Inc

BlossomHill Therapeutics, Inc. is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop innovative small molecule medicines that address significant unmet medical needs in cancer treatment. The Company is focused on its two clinical-stage programs: BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor being evaluated first in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS). It also has a preclinical-stage product candidate, BH-501284, that leverages a novel chemical scaffold to selectively target and modulate activated KRAS. The Company is also advancing multiple discovery-stage efforts focused on validated and emerging new oncology targets. It operates in the Healthcare sector.

BlossomHill Therapeutics is a good buy right now due to its recent FDA Fast Track designation for BH-30643, which has shown a 45% objective response rate in clinical trials. Despite a current price of $13.94 and a significant 20.25% drop over the past five days, the potential upside indicated by analyst price targets of $40 suggests a strong recovery opportunity. The main risk is the negative net income of -23,758,000 USD reported in Q2 2026, which reflects ongoing financial challenges.